Dapiprazole's effect upon accommodative recovery: is it due entirely to changes in depth of field?
We conducted a study to evaluate the ability of dapiprazole 0.5% ophthalmic solution to reverse accommodative loss brought about by mydriatic drugs having mild cycloplegic effects. To accomplish this, we analyzed data from several earlier randomized, masked clinical studies. Our composite data include over 90 subjects dilated with tropicamide. Tropicamide was used alone in 1% concentration, as well as in combination with phenylephrine, 2.5% and in the proprietary preparation, Paremyd (Allergan Pharmaceuticals). Accommodative amplitude and pupillary diameter were measured before instilling dilating drops and then again one-half hour later, immediately before instilling either dapiprazole or a placebo. Accommodative amplitude and pupil diameter measurements were then repeated four more times, on both the treatment and control eyes and at 30, 60, 120, and 180 min after instillation of the last drop of dapiprazole or placebo. We found accelerated "accommodative" recovery with dapiprazole for each of the three tropicamide-containing drugs used in our study. This is not surprising because some recovery of accommodative amplitude after dapiprazole's administration is expected. This is because dapiprazole accelerates pupillary recovery and a narrowing of the pupil gives rise to an increase in ocular depth of field. Rate of accommodative recovery with dapiprazole was found not to be significantly different for all three tropicamide-containing preparations tested (p > 0.05). Does dapiprazole produce improvement in amplitude of accommodation beyond that attributable to increased depth of field?(ABSTRACT TRUNCATED AT 250 WORDS)
Southeastern College of Optometry, North Miami Beach, Florida, USA.
J F
JF
Molinari
J H
JH
Carter
M E
ME
Johnson
D000065:Accommodation, Ocular / Q000187:drug effects*; D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000328:Adult; D003867:Depth Perception / Q000502:physiology*; D006801:Humans; D009184:Mydriatics / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010879:Piperazines; D011680:Pupil / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000494:pharmacology*; D014331:Tropicamide / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014794:Visual Fields
D000317:Adrenergic alpha-Antagonists; D009184:Mydriatics; D010879:Piperazines; D014230:Triazoles; C035289:dapiprazole; D014331:Tropicamide